AU560595B2 - Human-human hybridomas for neoplasms - Google Patents

Human-human hybridomas for neoplasms

Info

Publication number
AU560595B2
AU560595B2 AU17729/83A AU1772983A AU560595B2 AU 560595 B2 AU560595 B2 AU 560595B2 AU 17729/83 A AU17729/83 A AU 17729/83A AU 1772983 A AU1772983 A AU 1772983A AU 560595 B2 AU560595 B2 AU 560595B2
Authority
AU
Australia
Prior art keywords
human
monoclonal antibodies
cells
hybridomas
host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU17729/83A
Other languages
English (en)
Other versions
AU1772983A (en
Inventor
Mark C Glassy
Hideaki Hagiwara
Yoshihide Hagiwara
Harold H. Handley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU1772983A publication Critical patent/AU1772983A/en
Application granted granted Critical
Publication of AU560595B2 publication Critical patent/AU560595B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU17729/83A 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms Expired AU560595B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP57084843A JPS58201994A (ja) 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法
JP57-84843 1982-05-21

Publications (2)

Publication Number Publication Date
AU1772983A AU1772983A (en) 1983-12-16
AU560595B2 true AU560595B2 (en) 1987-04-09

Family

ID=13842073

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17729/83A Expired AU560595B2 (en) 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms

Country Status (13)

Country Link
EP (1) EP0109441B1 (cg-RX-API-DMAC7.html)
JP (2) JPS58201994A (cg-RX-API-DMAC7.html)
AT (1) ATE114189T1 (cg-RX-API-DMAC7.html)
AU (1) AU560595B2 (cg-RX-API-DMAC7.html)
CZ (1) CZ280677B6 (cg-RX-API-DMAC7.html)
DE (1) DE3382764T2 (cg-RX-API-DMAC7.html)
DK (1) DK164510C (cg-RX-API-DMAC7.html)
FI (1) FI86077C (cg-RX-API-DMAC7.html)
HU (1) HU190908B (cg-RX-API-DMAC7.html)
IN (1) IN157982B (cg-RX-API-DMAC7.html)
SK (1) SK356683A3 (cg-RX-API-DMAC7.html)
WO (1) WO1983004313A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA833686B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU589351B2 (en) * 1984-01-31 1989-10-12 Litton Bionetics, Inc. Tumor specific monoclonal antibodies

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4618577A (en) * 1983-02-09 1986-10-21 The Regents Of The University Of California Human-human hybridoma, CLNH5
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
CA1215331A (en) * 1983-03-04 1986-12-16 Tsann M. Chu Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4613576A (en) * 1983-03-09 1986-09-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cancer cells
US4693966A (en) * 1983-03-11 1987-09-15 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
GB2140030A (en) * 1983-04-08 1984-11-21 Kureha Chemical Ind Co Ltd Monoclonal antibody to human urinary bladder cancer
WO1985002411A1 (en) * 1983-11-25 1985-06-06 The University Of Melbourne Cell line and monoclonal antibody
DK144485A (da) * 1984-03-30 1985-10-01 Syntex Inc Monoklonale antistoffer
US4886745A (en) * 1984-03-30 1989-12-12 Syntex Inc. Monoclonal antibody specific for human basal cell surface antigen
JPS6133125A (ja) * 1984-07-25 1986-02-17 Morinaga & Co Ltd ヒト単クロ−ン性抗肺ガン細胞抗体
US4761377A (en) * 1984-10-15 1988-08-02 The Regents Of The University Of California Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
JPS61130300A (ja) * 1984-11-27 1986-06-18 ザ　ボ−ド　オブ　トラステイ−ズ　オブ　ザ　レランド　スタンフオ−ド　ジユニア　ユニバ−シテイ ヒトモノクロ−ナル抗体
US5106746A (en) * 1985-05-22 1992-04-21 E. I. Du Pont De Nemours And Company Process for the in vitro immunization of human splenocytes against tumor associated antigens
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
JPH0655680B2 (ja) * 1985-10-26 1994-07-27 萩原 義秀 悪性腫瘍用ヒトモノクロナル抗体複合剤
EP0222360A3 (en) * 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
JPH0767388B2 (ja) * 1986-01-13 1995-07-26 三菱化学株式会社 抗体産生細胞株の樹立方法
AU7165891A (en) * 1989-12-18 1991-07-18 Board Of Regents, The University Of Texas System Tumor-specific, cell surface-binding monoclonal antibodies
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
JPH04346792A (ja) * 1991-05-22 1992-12-02 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列
EP0528663B1 (en) * 1991-08-16 1997-10-29 Kabushiki Kaisha Toshiba Monoclonal antibody to a synaptophysin
KR20090068385A (ko) 1997-08-15 2009-06-26 츄가이 세이야꾸 가부시키가이샤 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제
ATE404216T1 (de) 1999-08-23 2008-08-15 Chugai Pharmaceutical Co Ltd Verstärker der hm1.24 antigen-expression
MXPA02003278A (es) 1999-10-01 2002-09-02 Chugai Pharmaceutical Co Ltd Prevencion y tratamiento de enfermedades relacionadas con la coagulacion sanguinea.
WO2002064159A1 (fr) 2001-02-07 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Remedes contre les tumeurs affectant les organes hematopoietiques
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP1475101B1 (en) 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
JP4489591B2 (ja) 2002-08-27 2010-06-23 中外製薬株式会社 タンパク質溶液製剤の安定化方法
SI1561756T1 (sl) 2002-09-11 2016-02-29 Chugai Seiyaku Kabushiki Kaisha Postopek čiščenja proteinov
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
ATE474921T1 (de) 2003-06-18 2010-08-15 Chugai Pharmaceutical Co Ltd Fucosetransporter
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
EP2270152A1 (en) 2003-12-03 2011-01-05 Chugai Seiyaku Kabushiki Kaisha Expression system using mammalian beta-actin promoter
US20080206229A1 (en) 2003-12-12 2008-08-28 Koichiro Ono Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
CN102702353A (zh) 2004-07-09 2012-10-03 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
WO2006067847A1 (ja) 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
EP1908482B1 (en) 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
AU2006300234B2 (en) 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
EP2338517A1 (en) 2005-11-14 2011-06-29 Ribomic Inc Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
ES2685915T3 (es) 2006-01-27 2018-10-15 Keio University Agentes terapéuticos para enfermedades que implican neovascularización coroidea
EP4218801A3 (en) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US20100080794A1 (en) 2006-04-14 2010-04-01 Takashi Tsuji Mutant polypeptide having effector function
CA2654623C (en) 2006-06-08 2016-07-26 Chugai Seiyaku Kabushiki Kaisha An anti-nr10/il-31ra antibody for use in preventing or treating an inflammatory disease
WO2007145227A1 (ja) 2006-06-14 2007-12-21 Chugai Seiyaku Kabushiki Kaisha 造血幹細胞増加促進剤
US20100150927A1 (en) 2006-07-13 2010-06-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
EP2047862B9 (en) 2006-07-21 2013-04-10 Chugai Seiyaku Kabushiki Kaisha Remedy for renal disease
DE602006013809D1 (de) 2006-07-24 2010-06-02 Facultad De Medicina Universid Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden
BRPI0713086A2 (pt) 2006-08-14 2012-10-09 Forerunner Pharma Res Co Ltd diagnóstico e tratamento de cáncer usando anticorpo anti-desmogleìna-3
JPWO2008032833A1 (ja) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Ａｄｃｃ活性を増強させた抗体及びその製造方法
JP5687822B2 (ja) 2006-10-12 2015-03-25 中外製薬株式会社 抗ｅｒｅｇ抗体を用いる癌の診断および治療
US20100061933A1 (en) 2006-10-20 2010-03-11 Naoki Kimura Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
WO2008081942A1 (ja) 2007-01-05 2008-07-10 The University Of Tokyo 抗prg-3抗体を用いる癌の診断および治療
EP2130552B1 (en) 2007-02-27 2016-06-15 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
US8722858B2 (en) 2007-06-25 2014-05-13 Chugai Seiyaku Kabushiki Kaisha Anti-Prominin-1 antibody having ADCC activity or CDC activity
JP5424330B2 (ja) 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
US8529895B2 (en) 2007-10-02 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Method for suppressing the development of graft-versus-host-disease by administering interleukin 6 receptor antibodies
US20120047586A9 (en) 2007-10-24 2012-02-23 Otsuka Chemical Co., Ltd Polypeptide having enhanced effector function
JP5676107B2 (ja) 2007-11-14 2015-02-25 中外製薬株式会社 抗ｇｐｒ４９抗体を用いる癌の診断および治療
TW200936160A (en) 2007-11-15 2009-09-01 Chugai Pharmaceutical Co Ltd Monoclonal antibodies that bind to anexelekto and uses thereof
KR20160074019A (ko) 2007-12-05 2016-06-27 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JP5848863B2 (ja) 2008-01-11 2016-01-27 国立大学法人 東京大学 抗ｃｌｄｎ６抗体
KR102269708B1 (ko) 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2116261A1 (en) 2008-05-07 2009-11-11 Institut Pasteur Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
US9226934B2 (en) 2008-06-02 2016-01-05 The University Of Tokyo Anti-cancer drug
JP5544290B2 (ja) 2008-06-05 2014-07-09 独立行政法人国立がん研究センター 神経浸潤抑制剤
EP2319869B1 (en) 2008-06-20 2016-08-17 National University Corporation Okayama University ANTIBODY AGAINST OXIDIZED LDL/ß²GPI COMPLEX AND USE OF THE SAME
AU2009331178A1 (en) 2008-12-26 2011-08-11 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-LGR7 antibody
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CA2760642A1 (en) 2009-05-01 2010-11-04 The University Of Tokyo Anti-cadherin antibody
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
AU2010278067B2 (en) 2009-07-31 2016-10-27 Shin Maeda Cancer metastasis inhibitor
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
RS57008B1 (sr) 2010-02-10 2018-05-31 Fujifilm Ri Pharma Co Ltd Anti-kadherin antitelo obeleženo radioaktivnim metalom
EP2540827A4 (en) 2010-02-26 2013-09-04 Chugai Pharmaceutical Co Ltd ANTI-ICAM3 ANTIBODIES AND USE THEREOF
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
EP4115906A1 (en) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
CN103491978A (zh) 2010-10-25 2014-01-01 明尼苏达大学评议会 用于治疗成胶质细胞瘤的治疗组合物
JP6006640B2 (ja) 2010-10-29 2016-10-12 株式会社ペルセウスプロテオミクス 高い内在化能力を有する抗ｃｄｈ３抗体
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
EP2749572A4 (en) 2011-08-23 2015-04-01 Chugai Pharmaceutical Co Ltd NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
CN109111524B (zh) 2011-10-31 2022-10-28 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
EP4458859A3 (en) 2012-04-04 2025-01-22 Perseus Proteomics Inc. Conjugate of anti-cdh3 (p-cadherin) antibody and drug
WO2014007402A1 (ja) 2012-07-06 2014-01-09 京都府公立大学法人 眼細胞の分化マーカーおよび分化制御
HK1210500A1 (en) 2012-09-27 2016-04-22 中外制药株式会社 Fgfr3 fusion gene and pharmaceutical drug targeting same
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
WO2016027859A1 (ja) 2014-08-20 2016-02-25 中外製薬株式会社 蛋白質溶液の粘度測定方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR101892883B1 (ko) 2015-02-27 2018-10-05 추가이 세이야쿠 가부시키가이샤 Il-6 관련 질환 치료용 조성물
KR20190133005A (ko) 2017-03-24 2019-11-29 젠야쿠코교가부시키가이샤 항 IgM/B 세포 표면 항원 이중 특이성 항체
EP3698808B1 (en) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US20210363238A1 (en) 2018-01-31 2021-11-25 Motokazu Kato Therapeutic agent for asthma containing il-6 inhibitor
AU2020227989A1 (en) 2019-02-28 2021-09-09 Juntendo Educational Foundation Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
JP7501876B2 (ja) 2019-04-17 2024-06-18 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
JP7684656B2 (ja) 2019-06-11 2025-05-28 小野薬品工業株式会社 免疫抑制剤
EP4134099A4 (en) 2020-04-06 2024-05-29 PhotoQ3 Inc. Medicine for killing tumor cells
CN116194473A (zh) 2020-07-28 2023-05-30 中外制药株式会社 包含新改造型抗体的具备针护罩的带针预充注射器制剂
CN116322763A (zh) 2020-08-27 2023-06-23 学校法人顺天堂 抗切断型突变calr-cd3双特异性抗体及医药组合物
AU2022232856A1 (en) 2021-03-12 2023-10-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treatment or prevention of myasthenia gravis
JP2024538654A (ja) 2021-10-04 2024-10-23 ノバルティス アーゲー 界面活性剤安定剤
IL313202A (en) 2021-12-01 2024-07-01 Chugai Pharmaceutical Co Ltd A method for preparing a formulation containing an antibody
WO2023163087A1 (ja) 2022-02-25 2023-08-31 学校法人順天堂 抗変異ｃａｌｒ抗体と他の薬剤とを組み合わせてなる医薬
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57502090A (cg-RX-API-DMAC7.html) * 1980-07-18 1982-11-25
NZ198851A (en) * 1980-11-07 1984-07-31 Wistar Inst Stable,continuous human myeloma cell line capable of hybridisation with antibody-producing cells:production of hybrid cell line

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU589351B2 (en) * 1984-01-31 1989-10-12 Litton Bionetics, Inc. Tumor specific monoclonal antibodies

Also Published As

Publication number Publication date
FI840219A0 (fi) 1984-01-19
DK25084A (da) 1984-01-20
FI86077B (fi) 1992-03-31
AU1772983A (en) 1983-12-16
DE3382764D1 (de) 1994-12-22
EP0109441A1 (en) 1984-05-30
HU190908B (en) 1986-12-28
DK25084D0 (da) 1984-01-20
DK164510C (da) 1992-11-23
CZ356683A3 (en) 1995-11-15
DE3382764T2 (de) 1995-03-16
SK279249B6 (sk) 1998-08-05
JPH0159878B2 (cg-RX-API-DMAC7.html) 1989-12-20
DK164510B (da) 1992-07-06
EP0109441B1 (en) 1994-11-17
FI840219L (fi) 1984-01-19
IN157982B (cg-RX-API-DMAC7.html) 1986-08-09
ATE114189T1 (de) 1994-12-15
EP0109441A4 (en) 1986-09-22
JPS58201994A (ja) 1983-11-25
WO1983004313A1 (en) 1983-12-08
JPS60501359A (ja) 1985-08-22
ZA833686B (en) 1984-09-26
FI86077C (fi) 1992-07-10
SK356683A3 (en) 1998-08-05
CZ280677B6 (cs) 1996-04-17

Similar Documents

Publication Publication Date Title
AU560595B2 (en) Human-human hybridomas for neoplasms
US4618577A (en) Human-human hybridoma, CLNH5
Epstein et al. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors.
US5185432A (en) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas
CA1242401A (en) Human monoclonal antibodies to cancer cells
EP1064551A1 (en) Development of human monoclonal antibodies and uses thereof
CA1247538A (en) Human-human hybridomas for solid tumors
EP0232871A2 (en) Human monoclonal antibody, hybridoma producing the same and its use
WO1986007089A1 (en) Murine hybridoma lym-2 and diagnostic antibody produced thereby
US5286647A (en) Human-human hybridomas for neoplasms
JPS59137497A (ja) 抗原特異的免疫グロブリン生産性ヒト／ヒトハイブリド−マ及びその生産する抗体
EP0203552B1 (en) Monoclonal antibodies for human non-small cell lung carcinomas
Dan et al. Human antiglioma monoclonal antibodies from patients with astrocytic tumors
NO165510B (no) Monoklonale antistoffer, samt anvendelse av dem in vitro for bestemmelse av naervaer av neoplasmer.
Hadas et al. Identification of a surface antigen, common to murine lung and Lewis lung carcinoma, by monoclonal antibody
JP2626979B2 (ja) ヒト癌細胞に対するモノクロナール抗体４ｃ１および該抗体を産生するハイブリドーマ
EP0347230A2 (en) Miniclones
Banerjee et al. Human monoclonal antibodies to neuroendocrine granules derived from tumor-infiltrating lymphocytes isolated from a primitive neuroectodermal tumor
JPH01243986A (ja) 抗ヒト固形癌ヒトモノクローナル抗体，抗体産生ハイブリドーマおよび抗体の製造法
EP0285052A2 (en) Monoclonal antibody
JPH0488998A (ja) 腫瘍特異的ヒト型モノクローナル抗体

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired